BCR-ABL V280G mutation, potential role in imatinib resistance: First case report
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.1177/1179554917702870 |
Resumo: | Export Date: 28 December 2017 Correspondence Address: Azevedo, A.P.; Department of Clinical Pathology, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, Estrada do Forte do Alto do Duque, Portugal; email: anpazevedo@gmail.com Chemicals/CAS: glycine, 56-40-6, 6000-43-7, 6000-44-8; hydroxyurea, 127-07-1; imatinib, 152459-95-5, 220127-57-1; nilotinib, 641571-10-0; valine, 7004-03-7, 72-18-4 References: Radich, J.P., Shah, N.P., Mauro, M.J., Integrating current treatment options for TKIresistant chronic myeloid leukemia (2014) Clin Adv Hematol Oncol, 12 (11), pp. 3-17; Savona, M.R., Molecular monitoring and minimal residual disease in the management of chronic myelogenous leukemia (2014) J Community Support Oncol, 12, pp. 171-178; Kantarjian, H.M., Cortes, J., La Rosée, P., Hochhaus, A., Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase (2010) Cancer, 116, pp. 1419-1430; Weisberg, E., Manley, P.W., Cowan-Jacob, S.W., Hochhaus, A., Griffin, J.D., Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia (2007) Nat Rev Cancer, 7, pp. 345-356; Nicolini, F.E., Corm, S., Lê, Q.H., Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP) (2006) Leukemia, 20, pp. 1061-1066; Soverini, S., Colarossi, S., Gnani, A., Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia (2006) Clin Cancer Res, 12, pp. 7374-7379; Sokal, J.E., Cox, E.B., Baccarani, M., Prognostic discrimination in “good-risk” chronic granulocytic leukemia (1984) Blood, 63, pp. 789-799; Hasford, J., Pfirrmann, M., Hehlmann, R., A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group (1998) J Natl Cancer Inst, 90, pp. 850-858; Hasford, J., Baccarani, M., Hoffmann, V., Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score (2011) Blood, 118, pp. 686-692; Gromicho, M., Magalhães, M., Torres, F., Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib (2013) Oncol Rep, 29, pp. 741-750; Liu, L.L., Li, F., Pao, W., Michor, F., Dose-dependent mutation rates determine optimum erlotinib dosing strategies for EGFR mutant non-small cell lung cancer patients (2015) Plos ONE, 10; Tang, C., Schafranek, L., Watkins, D.B., Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: Investigating resistance pathways (2011) Leuk Lymphoma, 52, pp. 2139-2147; Hayakawa, H., Ichihara, E., Ohashi, K., Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model (2013) Cancer Sci, 104, pp. 1440-1446; Santos, F.P., Kantarjian, H., Fava, C., Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia (2010) Br J Haematol, 150, pp. 303-312; Van Obbergh, F., Knoops, L., Devos, T., The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study [published online ahead of print December 22, 2016] Clin Biochem; Vine, J., Cohen, S.B., Ruchlemer, R., Polymorphisms in the human organic cation transporter and the multidrug resistance gene: Correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia (2014) Leuk Lymphoma, 55, pp. 2525-2531; Sundar, H., Radich, J., Optimizing patient care in chronic phase Chronic Myelogenous Leukemia: A multidisciplinary approach (2016) J Natl Compr Cancer Netw, 14, pp. s1-s6; McDougall, J., Ramsey, S.D., Radich, J., What happens when imatinib goes generic? (2016) J Natl Compr Canc Netw, 14, pp. 128-131; Hochhaus, A., Saglio, G., Hughes, T.P., Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial (2016) Leukemia, 30, pp. 1044-1054; Cortes, J.E., Saglio, G., Kantarjian, H.M., Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial (2016) J Clin Oncol, 34, pp. 2333-2340; Druker, B.J., Guilhot, F., O’Brien, S.G., Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia (2006) N Engl J Med, 355, pp. 2408-2417; Soverini, S., De Benedittis, C., Mancini, M., Martinelli, G., Mutations in the BCRABL1 kinase domain and elsewhere in chronic myeloid leukemia (2015) Clin Lymphoma Myeloma Leuk, 15, pp. S120-S128; O’Brien, S., Radich, J.P., Abboud, C.N., Chronic myelogenous leukemia, version 1.2015 (2014) J Natl Compr Canc Netw, 12, pp. 1590-1610; Baccarani, M., Deininger, M.W., Rosti, G., European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 (2013) Blood, 122, pp. 872-884; Deininger, M.W., Molecular monitoring in CML and the prospects for treatmentfree remissions (2015) Hematology am Soc Hematol Educ Program, 2015, pp. 257-263; Soverini, S., Hochhaus, A., Nicolini, F.E., BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet (2011) Blood, 118, pp. 1208-1215; Soverini, S., Branford, S., Nicolini, F.E., Implications of BCR-ABL1 kinase domain- mediated resistance in chronic myeloid leukemia (2014) Leuk Res, 38, pp. 10-20; Machova Polakova, K., Kulvait, V., Benesova, A., Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase (2015) J Cancer Res Clin Oncol, 141, pp. 887-899; Jabbour, E., Saglio, G., Hughes, T.P., Kantarjian, H., Suboptimal responses in chronic myeloid leukemia: Implications and management strategies (2012) Cancer, 118, pp. 1181-1191; Gruber, T.A., Chang, M.S., Sposto, R., Müschen, M., Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia (2010) Cancer Res, 70, pp. 7411-7420 |
id |
RCAP_edf897809651f56fc4d3e0a468d53060 |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/27823 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
BCR-ABL V280G mutation, potential role in imatinib resistance: First case reportBCR-ABLCMLImatinibMutationNilotinibalpha interferonBCR ABL proteinglycinehydroxyureaimatinibnilotinibvalineagedamino acid substitutionArticleBCR ABL genecase reportchromosome 22chromosome 9chronic myeloid leukemiaclinical articledisease coursedrug dose escalationdrug withdrawalEUTOS scorefemalegenegene mutationgene sequenceHasford scorehumanleukodermareverse transcription polymerase chain reactionSokal scoresplenomegalySDG 3 - Good Health and Well-beingExport Date: 28 December 2017 Correspondence Address: Azevedo, A.P.; Department of Clinical Pathology, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, Estrada do Forte do Alto do Duque, Portugal; email: anpazevedo@gmail.com Chemicals/CAS: glycine, 56-40-6, 6000-43-7, 6000-44-8; hydroxyurea, 127-07-1; imatinib, 152459-95-5, 220127-57-1; nilotinib, 641571-10-0; valine, 7004-03-7, 72-18-4 References: Radich, J.P., Shah, N.P., Mauro, M.J., Integrating current treatment options for TKIresistant chronic myeloid leukemia (2014) Clin Adv Hematol Oncol, 12 (11), pp. 3-17; Savona, M.R., Molecular monitoring and minimal residual disease in the management of chronic myelogenous leukemia (2014) J Community Support Oncol, 12, pp. 171-178; Kantarjian, H.M., Cortes, J., La Rosée, P., Hochhaus, A., Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase (2010) Cancer, 116, pp. 1419-1430; Weisberg, E., Manley, P.W., Cowan-Jacob, S.W., Hochhaus, A., Griffin, J.D., Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia (2007) Nat Rev Cancer, 7, pp. 345-356; Nicolini, F.E., Corm, S., Lê, Q.H., Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP) (2006) Leukemia, 20, pp. 1061-1066; Soverini, S., Colarossi, S., Gnani, A., Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia (2006) Clin Cancer Res, 12, pp. 7374-7379; Sokal, J.E., Cox, E.B., Baccarani, M., Prognostic discrimination in “good-risk” chronic granulocytic leukemia (1984) Blood, 63, pp. 789-799; Hasford, J., Pfirrmann, M., Hehlmann, R., A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group (1998) J Natl Cancer Inst, 90, pp. 850-858; Hasford, J., Baccarani, M., Hoffmann, V., Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score (2011) Blood, 118, pp. 686-692; Gromicho, M., Magalhães, M., Torres, F., Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib (2013) Oncol Rep, 29, pp. 741-750; Liu, L.L., Li, F., Pao, W., Michor, F., Dose-dependent mutation rates determine optimum erlotinib dosing strategies for EGFR mutant non-small cell lung cancer patients (2015) Plos ONE, 10; Tang, C., Schafranek, L., Watkins, D.B., Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: Investigating resistance pathways (2011) Leuk Lymphoma, 52, pp. 2139-2147; Hayakawa, H., Ichihara, E., Ohashi, K., Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model (2013) Cancer Sci, 104, pp. 1440-1446; Santos, F.P., Kantarjian, H., Fava, C., Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia (2010) Br J Haematol, 150, pp. 303-312; Van Obbergh, F., Knoops, L., Devos, T., The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study [published online ahead of print December 22, 2016] Clin Biochem; Vine, J., Cohen, S.B., Ruchlemer, R., Polymorphisms in the human organic cation transporter and the multidrug resistance gene: Correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia (2014) Leuk Lymphoma, 55, pp. 2525-2531; Sundar, H., Radich, J., Optimizing patient care in chronic phase Chronic Myelogenous Leukemia: A multidisciplinary approach (2016) J Natl Compr Cancer Netw, 14, pp. s1-s6; McDougall, J., Ramsey, S.D., Radich, J., What happens when imatinib goes generic? (2016) J Natl Compr Canc Netw, 14, pp. 128-131; Hochhaus, A., Saglio, G., Hughes, T.P., Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial (2016) Leukemia, 30, pp. 1044-1054; Cortes, J.E., Saglio, G., Kantarjian, H.M., Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial (2016) J Clin Oncol, 34, pp. 2333-2340; Druker, B.J., Guilhot, F., O’Brien, S.G., Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia (2006) N Engl J Med, 355, pp. 2408-2417; Soverini, S., De Benedittis, C., Mancini, M., Martinelli, G., Mutations in the BCRABL1 kinase domain and elsewhere in chronic myeloid leukemia (2015) Clin Lymphoma Myeloma Leuk, 15, pp. S120-S128; O’Brien, S., Radich, J.P., Abboud, C.N., Chronic myelogenous leukemia, version 1.2015 (2014) J Natl Compr Canc Netw, 12, pp. 1590-1610; Baccarani, M., Deininger, M.W., Rosti, G., European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 (2013) Blood, 122, pp. 872-884; Deininger, M.W., Molecular monitoring in CML and the prospects for treatmentfree remissions (2015) Hematology am Soc Hematol Educ Program, 2015, pp. 257-263; Soverini, S., Hochhaus, A., Nicolini, F.E., BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet (2011) Blood, 118, pp. 1208-1215; Soverini, S., Branford, S., Nicolini, F.E., Implications of BCR-ABL1 kinase domain- mediated resistance in chronic myeloid leukemia (2014) Leuk Res, 38, pp. 10-20; Machova Polakova, K., Kulvait, V., Benesova, A., Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase (2015) J Cancer Res Clin Oncol, 141, pp. 887-899; Jabbour, E., Saglio, G., Hughes, T.P., Kantarjian, H., Suboptimal responses in chronic myeloid leukemia: Implications and management strategies (2012) Cancer, 118, pp. 1181-1191; Gruber, T.A., Chang, M.S., Sposto, R., Müschen, M., Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia (2010) Cancer Res, 70, pp. 7411-7420Introduction: The identification of BCR-ABL expression as the defining leukemogenic event in chronic myeloid leukemia (CML) and the introduction of BCR-ABL tyrosine kinase inhibitors in 2001 have revolutionized disease management, leading to a reduction in mortality rates and accordingly an increase in the estimated prevalence of CML. Case report: Based on medical records and clinical follow-up, the authors present the case of a Philadelphia chromosome–positive CML patient who developed resistance to imatinib. Quantitative reverse transcription-polymerase chain reaction testing revealed a V280G BCR-ABL mutation. Discussion and conclusions: This is the first report describing a new BCR-ABL kinase domain mutation—V280G—that might be associated with resistance to imatinib. Approximately 15% to 30% of patients treated with imatinib discontinue treatment due to resistance or intolerance. More than 90 BCR-ABL mutations were detected so far, conferring variable degrees of drug resistance, with consequent clinical, therapeutic, and prognostic impact. © The Author(s) 2017.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Centre for Toxicogenomics and Human Health (ToxOmics)RUNAzevedo, A.P.Reichert, A.Afonso, C.Alberca, M.D.Tavares, P.Lima, F.2018-01-09T11:31:41Z20172017-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.1177/1179554917702870eng1179-5549PURE: 3409376https://www.scopus.com/inward/record.uri?eid=2-s2.0-85034627995&doi=10.1177%2f1179554917702870&partnerID=40&md5=2f9e733c9917a0a3235f85279d0de323https://doi.org/10.1177/1179554917702870info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T04:14:44Zoai:run.unl.pt:10362/27823Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:28:46.083079Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
BCR-ABL V280G mutation, potential role in imatinib resistance: First case report |
title |
BCR-ABL V280G mutation, potential role in imatinib resistance: First case report |
spellingShingle |
BCR-ABL V280G mutation, potential role in imatinib resistance: First case report Azevedo, A.P. BCR-ABL CML Imatinib Mutation Nilotinib alpha interferon BCR ABL protein glycine hydroxyurea imatinib nilotinib valine aged amino acid substitution Article BCR ABL gene case report chromosome 22 chromosome 9 chronic myeloid leukemia clinical article disease course drug dose escalation drug withdrawal EUTOS score female gene gene mutation gene sequence Hasford score human leukoderma reverse transcription polymerase chain reaction Sokal score splenomegaly SDG 3 - Good Health and Well-being |
title_short |
BCR-ABL V280G mutation, potential role in imatinib resistance: First case report |
title_full |
BCR-ABL V280G mutation, potential role in imatinib resistance: First case report |
title_fullStr |
BCR-ABL V280G mutation, potential role in imatinib resistance: First case report |
title_full_unstemmed |
BCR-ABL V280G mutation, potential role in imatinib resistance: First case report |
title_sort |
BCR-ABL V280G mutation, potential role in imatinib resistance: First case report |
author |
Azevedo, A.P. |
author_facet |
Azevedo, A.P. Reichert, A. Afonso, C. Alberca, M.D. Tavares, P. Lima, F. |
author_role |
author |
author2 |
Reichert, A. Afonso, C. Alberca, M.D. Tavares, P. Lima, F. |
author2_role |
author author author author author |
dc.contributor.none.fl_str_mv |
NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) Centre for Toxicogenomics and Human Health (ToxOmics) RUN |
dc.contributor.author.fl_str_mv |
Azevedo, A.P. Reichert, A. Afonso, C. Alberca, M.D. Tavares, P. Lima, F. |
dc.subject.por.fl_str_mv |
BCR-ABL CML Imatinib Mutation Nilotinib alpha interferon BCR ABL protein glycine hydroxyurea imatinib nilotinib valine aged amino acid substitution Article BCR ABL gene case report chromosome 22 chromosome 9 chronic myeloid leukemia clinical article disease course drug dose escalation drug withdrawal EUTOS score female gene gene mutation gene sequence Hasford score human leukoderma reverse transcription polymerase chain reaction Sokal score splenomegaly SDG 3 - Good Health and Well-being |
topic |
BCR-ABL CML Imatinib Mutation Nilotinib alpha interferon BCR ABL protein glycine hydroxyurea imatinib nilotinib valine aged amino acid substitution Article BCR ABL gene case report chromosome 22 chromosome 9 chronic myeloid leukemia clinical article disease course drug dose escalation drug withdrawal EUTOS score female gene gene mutation gene sequence Hasford score human leukoderma reverse transcription polymerase chain reaction Sokal score splenomegaly SDG 3 - Good Health and Well-being |
description |
Export Date: 28 December 2017 Correspondence Address: Azevedo, A.P.; Department of Clinical Pathology, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, Estrada do Forte do Alto do Duque, Portugal; email: anpazevedo@gmail.com Chemicals/CAS: glycine, 56-40-6, 6000-43-7, 6000-44-8; hydroxyurea, 127-07-1; imatinib, 152459-95-5, 220127-57-1; nilotinib, 641571-10-0; valine, 7004-03-7, 72-18-4 References: Radich, J.P., Shah, N.P., Mauro, M.J., Integrating current treatment options for TKIresistant chronic myeloid leukemia (2014) Clin Adv Hematol Oncol, 12 (11), pp. 3-17; Savona, M.R., Molecular monitoring and minimal residual disease in the management of chronic myelogenous leukemia (2014) J Community Support Oncol, 12, pp. 171-178; Kantarjian, H.M., Cortes, J., La Rosée, P., Hochhaus, A., Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase (2010) Cancer, 116, pp. 1419-1430; Weisberg, E., Manley, P.W., Cowan-Jacob, S.W., Hochhaus, A., Griffin, J.D., Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia (2007) Nat Rev Cancer, 7, pp. 345-356; Nicolini, F.E., Corm, S., Lê, Q.H., Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP) (2006) Leukemia, 20, pp. 1061-1066; Soverini, S., Colarossi, S., Gnani, A., Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia (2006) Clin Cancer Res, 12, pp. 7374-7379; Sokal, J.E., Cox, E.B., Baccarani, M., Prognostic discrimination in “good-risk” chronic granulocytic leukemia (1984) Blood, 63, pp. 789-799; Hasford, J., Pfirrmann, M., Hehlmann, R., A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group (1998) J Natl Cancer Inst, 90, pp. 850-858; Hasford, J., Baccarani, M., Hoffmann, V., Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score (2011) Blood, 118, pp. 686-692; Gromicho, M., Magalhães, M., Torres, F., Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib (2013) Oncol Rep, 29, pp. 741-750; Liu, L.L., Li, F., Pao, W., Michor, F., Dose-dependent mutation rates determine optimum erlotinib dosing strategies for EGFR mutant non-small cell lung cancer patients (2015) Plos ONE, 10; Tang, C., Schafranek, L., Watkins, D.B., Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: Investigating resistance pathways (2011) Leuk Lymphoma, 52, pp. 2139-2147; Hayakawa, H., Ichihara, E., Ohashi, K., Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model (2013) Cancer Sci, 104, pp. 1440-1446; Santos, F.P., Kantarjian, H., Fava, C., Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia (2010) Br J Haematol, 150, pp. 303-312; Van Obbergh, F., Knoops, L., Devos, T., The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study [published online ahead of print December 22, 2016] Clin Biochem; Vine, J., Cohen, S.B., Ruchlemer, R., Polymorphisms in the human organic cation transporter and the multidrug resistance gene: Correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia (2014) Leuk Lymphoma, 55, pp. 2525-2531; Sundar, H., Radich, J., Optimizing patient care in chronic phase Chronic Myelogenous Leukemia: A multidisciplinary approach (2016) J Natl Compr Cancer Netw, 14, pp. s1-s6; McDougall, J., Ramsey, S.D., Radich, J., What happens when imatinib goes generic? (2016) J Natl Compr Canc Netw, 14, pp. 128-131; Hochhaus, A., Saglio, G., Hughes, T.P., Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial (2016) Leukemia, 30, pp. 1044-1054; Cortes, J.E., Saglio, G., Kantarjian, H.M., Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial (2016) J Clin Oncol, 34, pp. 2333-2340; Druker, B.J., Guilhot, F., O’Brien, S.G., Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia (2006) N Engl J Med, 355, pp. 2408-2417; Soverini, S., De Benedittis, C., Mancini, M., Martinelli, G., Mutations in the BCRABL1 kinase domain and elsewhere in chronic myeloid leukemia (2015) Clin Lymphoma Myeloma Leuk, 15, pp. S120-S128; O’Brien, S., Radich, J.P., Abboud, C.N., Chronic myelogenous leukemia, version 1.2015 (2014) J Natl Compr Canc Netw, 12, pp. 1590-1610; Baccarani, M., Deininger, M.W., Rosti, G., European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 (2013) Blood, 122, pp. 872-884; Deininger, M.W., Molecular monitoring in CML and the prospects for treatmentfree remissions (2015) Hematology am Soc Hematol Educ Program, 2015, pp. 257-263; Soverini, S., Hochhaus, A., Nicolini, F.E., BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet (2011) Blood, 118, pp. 1208-1215; Soverini, S., Branford, S., Nicolini, F.E., Implications of BCR-ABL1 kinase domain- mediated resistance in chronic myeloid leukemia (2014) Leuk Res, 38, pp. 10-20; Machova Polakova, K., Kulvait, V., Benesova, A., Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase (2015) J Cancer Res Clin Oncol, 141, pp. 887-899; Jabbour, E., Saglio, G., Hughes, T.P., Kantarjian, H., Suboptimal responses in chronic myeloid leukemia: Implications and management strategies (2012) Cancer, 118, pp. 1181-1191; Gruber, T.A., Chang, M.S., Sposto, R., Müschen, M., Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia (2010) Cancer Res, 70, pp. 7411-7420 |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017 2017-01-01T00:00:00Z 2018-01-09T11:31:41Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.1177/1179554917702870 |
url |
https://doi.org/10.1177/1179554917702870 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1179-5549 PURE: 3409376 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85034627995&doi=10.1177%2f1179554917702870&partnerID=40&md5=2f9e733c9917a0a3235f85279d0de323 https://doi.org/10.1177/1179554917702870 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137913425887232 |